Global Blood Therapeutics has been granted a patent for a crystalline form of Compound I, a potential therapeutic compound. The patent covers the preparation, characterization, and use of this form of Compound I. GlobalData’s report on Global Blood Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Global Blood Therapeutics, was a key innovation area identified from patents.
Crystalline form of compound i for medical use
The granted patent (Publication Number: US11851424B2) discloses a crystalline Compound I Form I with specific characteristics, including a unique X-ray powder diffractogram and a differential scanning calorimetry (DSC) curve showing an endotherm at about 111°C. The compound also has defined unit cell parameters, making it distinguishable and identifiable.
Additionally, the patent covers other crystalline forms of Compound I, such as Material II and HCl Form A, each with their own distinct X-ray powder diffractogram and DSC curve characteristics. The patent further extends to pharmaceutical compositions containing the crystalline Compound I Form I, either alone or in combination with other therapeutic agents, for treating disorders mediated by hemoglobin, particularly sickle cell disease. Methods for increasing oxygen affinity of hemoglobin S and treating sickle cell disease by administering the crystalline Compound I Form I are also claimed in the patent, highlighting its potential therapeutic applications in addressing hemoglobin-related disorders.
To know more about GlobalData’s detailed insights on Global Blood Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.